U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07192640) titled 'Intravenous Tranexamic Acid' on Sept. 12.
Brief Summary: Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Obese Patients
Obese Patients With Bariatric Surgery
Bleeding
Intervention:
DRUG: After induction of anaesthesia tranexamic acid will be administered at the start of s...